Case Study – DASA
DASA leverages on the SOPHiA GENETICS multimodal approach in the fight against cancer
Country
Brazil
Research Challenge
Personalized medicine
Solution
SOPHiA DDM™ for Radiomics and SOPHiA DDM™ Trial Match
Dasa operates a network of diagnostic medicine, hospitals and a care management company, connecting spaces, technologies, knowledge and multiple specialties. Its diagnostic medicine service, including clinical analysis, diagnostic imaging and genetic medicine, is internationally recognized for quality.
Dasa has more than 40,000 employees, contact with 250,000 doctors and take care of 20 million patients per year. The company also performs more than 260 million exams through 900 ambulatories and inpatient sites across the country.
Challenge
Clinicians from Dasa sought to better understand how to orient patients to personalized medicine, confidently detect disease-causing variants, select the right therapy for each and monitor the efficacy of the treatment. They were in need for a solution to optimize use of oncology data collected throughout the diagnostic journey of a patient.
Solution
In 2016 Dasa partnered with SOPHiA GENETICS to accurately analyze, organize and store the hereditary and hematologic disorder data produced from its genetic unit GeneOne in the context of hereditary and hematologic disorders.
In 2020, Dasa expanded its collaboration with SOPHiA GENETICS and adopted SOPHiA DDM™ for Radiomics and SOPHiA DDM™ Trial Match.
Results
Dasa has accelerated clinical trial recruitment, informed by biomarkers and the genetic variants identified by the SOPHiA DDM™ platform. Dasa’s hospital network, Ímpar, joined the community of SOPHiA DDM™ platform users to engage with peers, share knowledge and collaborate with other experts.
With the help of the SOPHiA DDM™ platform, Dasa performs an exponentially growing number of genomic analyses in various areas of oncology.
In addition, SOPHiA DDM™ for Radiomics allows Dasa radiologists and oncologists to make more data-driven informed decisions and enable individualized follow-up of patients throughout their care journey.
“SOPHiA GENETICS has become our partner of choice for Data-Driven Medicine as we help deliver transformative progress for patients thanks to the multimodal data approach here in Latin America, first by integrating radiomics and now clinical trials. Engaging in [SOPHiA DDM™] Trial Match will help clinicians from Dasa understand better how to follow up, treat and orientate patients towards a more personalized medicine.”
Andreza Almeida Senerchia
Head of Clinical Research at Dasa
Related Case Studies
Genomic Diagnostics, Australia
Genomic Diagnostics improve equity of access to hereditary cancer genomic analysis in Australia with the SOPHiA DDM™ Hereditary Cancer Solution v1.1.
TomaLab Advanced Biomedical Assays
A Clinical Case Study about the value of the SOPHiA DDM™ HRD Dx Solution in clinical routine
The Andalusian Health Service use the CE IVD-marked SOPHiA DDM™️ Dx Hereditary Cancer Solution to detect an Alu insertion (Clinical Decision Support Only) in an ovarian cancer case
The SOPHiA DDM™️ Platform enables the quick and confident assessment of ~1000 hereditary cancer samples per year.
The Andalusian Health Service address a colorectal cancer case with the CE IVD-marked SOPHiA DDM™️ Dx Hereditary Cancer Solution
The CNV detection algorithm in SOPHiA DDM™️ efficiently identified a complex duplication in MSH2.
Ontario Group of Hospitals use a future-proof custom SOPHiA DDM™ Comprehensive Hereditary Cancer Solution to be in line with Ontario guidelines.
Hospitals maximize efficiency of their laboratory workflow, fulfil updated Ontario guidelines and keep testing in-house.
The Andalusian Health Service conduct trio analysis with the SOPHiA DDM™ Platform to identify the underlying cause of 2 neonatal deaths
The SOPHiA DDM Platform was a very useful tool for resolving this complex case.
Motol University Hospital in Prague discover a novel cause of inherited cardiac disease with the SOPHiA Clinical Exome Solution v3
The laboratory finds the community frequency tool very useful for making quick decisions about whether to deeply investigate a variant.
Collaborating with the Bambino Gesù Children’s Hospital to develop the SOPHiA Nephropathies Solution
SOPHiA DDM™ enables the laboratory to process a large number of samples in a simple way to gain exhaustive insights.
Indian research hospital chose SOPHiA DDM™ for the analysis of gene fusion events
SOPHiA DDM™’s unique community frequency tool helps to assess solid tumor variant frequency in the hospital’s cohort and globally.
University of Sassari adopts SOPHiA DDM™ for SARS-CoV-2 research and surveillance
SOPHiA DDM™ saves the reference center a massive amount of data analysis time so they can focus more on interpretation.